News

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader…

2 years ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…

2 years ago

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy

Canadian patients living with this ultra-rare condition welcome this new treatment optionBOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Chiesi Global…

2 years ago

Uncle Bud’s to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

CBD Body Revive Spray All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class, UltraShear-processed Nano CBD Multi-Patented Nanoemulsification Platform Enables…

2 years ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week…

2 years ago

Safe Supply Streaming Endorses B.C. Government’s Expansion of Safer-Supply Program amid Drug Crisis

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2024) - Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe…

2 years ago

Awakn Life Sciences Announces Conditional Approval of CSE Listing

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a…

2 years ago

ScanDiags Accelerates Drive to Commercialize Its ImagoPlus(TM) Artificial Intelligence Software Platform for Medical Imaging

The company is partnering with OMNIA Global to support capital markets engagement and strategic commercialization activitiesVancouver, Canada and Zurich, Switzerland--(Newsfile…

2 years ago

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid)…

2 years ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results…

2 years ago